NZ230854A - 1,4 dihydropyridine derivatives, intermediate compound and pharmaceutical compositions - Google Patents

1,4 dihydropyridine derivatives, intermediate compound and pharmaceutical compositions

Info

Publication number
NZ230854A
NZ230854A NZ230854A NZ23085489A NZ230854A NZ 230854 A NZ230854 A NZ 230854A NZ 230854 A NZ230854 A NZ 230854A NZ 23085489 A NZ23085489 A NZ 23085489A NZ 230854 A NZ230854 A NZ 230854A
Authority
NZ
New Zealand
Prior art keywords
pharmaceutical compositions
intermediate compound
dihydropyridine derivatives
methyl
dihydropyridine
Prior art date
Application number
NZ230854A
Inventor
Jean-Louis Deglion
Yves-Michel Gargouil
Jean-Paul Vilaine
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of NZ230854A publication Critical patent/NZ230854A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

(-)2{[2-(2-Aminoethoxy)ethoxy]methyl}-4-(2,3-dichlorophenyl)-3-etho xycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine compound of formula I <IMAGE> and its addition salts with a pharmaceutically acceptable inorganic or organic acid. Medication.
NZ230854A 1989-07-04 1989-10-02 1,4 dihydropyridine derivatives, intermediate compound and pharmaceutical compositions NZ230854A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8908920A FR2649395B1 (en) 1989-07-04 1989-07-04 NEW DERIVATIVE OF 1,4-DIHYDRO PYRIDINE NAMED (-) I1(((2-AMINO ETHOXY)-2 ETHOXY) METHYLI1) -2 (2,3-DICHLORO-PHENYL)-4 ETHOXYCARBONYL-3 METHOXYCARBONYL -5 METHYL-6 DIHYDRO-1,4 PYRIDINE, ITS PREPARATION PROCESS AND THE COMPOSITIONS WHICH CONTAIN IT

Publications (1)

Publication Number Publication Date
NZ230854A true NZ230854A (en) 1991-02-26

Family

ID=9383413

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ230854A NZ230854A (en) 1989-07-04 1989-10-02 1,4 dihydropyridine derivatives, intermediate compound and pharmaceutical compositions

Country Status (14)

Country Link
EP (1) EP0406502B1 (en)
JP (1) JPH0720934B2 (en)
AT (1) ATE122340T1 (en)
AU (1) AU619049B2 (en)
CA (1) CA1327582C (en)
DE (1) DE68922605T2 (en)
DK (1) DK478989A (en)
ES (1) ES2074472T3 (en)
FR (1) FR2649395B1 (en)
IE (1) IE67059B1 (en)
NZ (1) NZ230854A (en)
OA (1) OA09136A (en)
PT (1) PT91869B (en)
ZA (1) ZA897349B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652083B1 (en) * 1989-09-20 1992-01-24 Ador Cie NOVEL PROCESS FOR SEPARATING OPTICAL ISOMERS OF 1,4-DIHYDRO PYRIDINE DERIVATIVES.
FR2686879B1 (en) * 1992-02-05 1994-03-18 Adir Cie NOVEL 1,4-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE4444864A1 (en) * 1994-12-16 1996-06-20 Bayer Ag Use of 5-acyl-1,4-dihydropyridines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (en) * 1982-03-11 1991-12-09 Pfizer CHANGES FOR THE PREPARATION FOR THE PREPARATION OF 2-Amino-CO-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-2-D-Hydroxy
FR2602231B1 (en) * 1986-08-04 1988-10-28 Adir NOVEL 1,4-DIHYDRO PYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
EP0406502B1 (en) 1995-05-10
ZA897349B (en) 1990-09-26
EP0406502A1 (en) 1991-01-09
ES2074472T3 (en) 1995-09-16
IE67059B1 (en) 1996-02-21
DK478989A (en) 1991-01-05
IE893103A1 (en) 1991-01-16
OA09136A (en) 1991-10-31
DE68922605D1 (en) 1995-06-14
FR2649395B1 (en) 1992-11-06
DE68922605T2 (en) 1996-01-04
ATE122340T1 (en) 1995-05-15
AU4239089A (en) 1991-01-10
FR2649395A1 (en) 1991-01-11
JPH0720934B2 (en) 1995-03-08
AU619049B2 (en) 1992-01-16
PT91869B (en) 1995-07-18
PT91869A (en) 1991-03-20
JPH0344371A (en) 1991-02-26
DK478989D0 (en) 1989-09-28
CA1327582C (en) 1994-03-08

Similar Documents

Publication Publication Date Title
NZ228893A (en) Substituted quinoline and naphthyridine derivatives and pharmaceutical compositions
NO932607D0 (en) PIPERIDE INGREDIENTS AND THE USE OF THESE
HUT58709A (en) Process for producing n-aryl-piperazin-acetamide derivatives and pharmaceutical compositions containing them
ZA921341B (en) 4-((2-benzothiazolyl)methylamino)-a-(3,4-difluorophenoxy) methyl)-1-piperidineethanol.
ATE97810T1 (en) INJECTABLE CEPHALOSPORIN PRODUCTS AND THEIR USE.
NZ230854A (en) 1,4 dihydropyridine derivatives, intermediate compound and pharmaceutical compositions
AU656674B2 (en) New thiochroman compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
EP0535250A4 (en) Novel compounds and use thereof as medicine
NO20000750D0 (en) Procedure for reducing platelet count
ES2000475A6 (en) Cephalosporins, their preparation and formulations.
AU4209693A (en) Novel piperidine derivatives and process for preparation thereof
EP0294292A3 (en) Derivative of benzoûb¨thiophene-7-carboxylic acid, process for its preparation and pharmaceutical compositions containing it
OA09471A (en) &#34;Novel substituted benzothiazolinones, their preparation process and pharmaceutical compositions which contain them&#34;.